Label Image (Lbl500902908)
Losartan
Product Images NDC 50090-2908
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan (NDC 50090-2908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Losartan 01)
Figure 1 (Losartan 02)
Figure 2 (Losartan 03)
This figure shows the percentage of patients with fatal or non-fatal stroke. There is no data available for the Atenolol treatment group. The Losartan potassium treatment group had an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted over a period of 66 months with data points recorded at 6-month intervals.*
Figure 3 (Losartan 04)
This appears to be a statistical report comparing the effectiveness of Losartan potassium and atenolol in reducing the incidence of stroke, fatal and non-fatal, among patients with diabetes and a history of CVD. The study involved 9193 patients under the age of 65, with 3489 females and 5704 males. Other demographic characteristics such as ethnicity/race are not available. The table presents data on the number of patients with particular health conditions such as hypertension and diabetes and the rate of occurrence of events under each medication. The Hazard Ratio with 35% CI indicates the probability of one medication being more effective than the other.*
Figure 4 (Losartan 05)
This appears to be a table showing the percentage of patients with an event and some statistics related to a study that compared losartan potassium to placebo over the course of 48 months. The table shows that 60% of patients on losartan potassium had an event compared to 40% of patients on placebo. The risk reduction is calculated to be 16.1%, with a p-value of 0.0022.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
